
|Articles|May 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 5
- Volume 16
- Issue 5
AVEO and Schering-Plough to Develop Anti-HGF Antibody
AVEO and Schering-Plough to Develop Anti-HGF Antibody
Advertisement
CAMBRIDGE, MassachusettsAVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.
Articles in this issue
over 19 years ago
Escalating Drug Costs Could Provoke Consumer Backlashover 19 years ago
Large Study Casts Doubt on Value of CADover 19 years ago
Cetuximab Does Not Increase Mucositis in H&N Cancerover 19 years ago
2004 Update Shows Continued Lower Breast Ca Incidenceover 19 years ago
Reclast Single-Dose Infusion Approved for Paget's Diseaseover 19 years ago
Fragmin Approved for VTE in Cancer Ptsover 19 years ago
New Phase III Trial of Genasense in Advanced Melanoma Plannedover 19 years ago
Cervical Cancer Vaccines Show Sustained Protectionover 19 years ago
The 'New' Medicare: Passive Payer No More; PQRI Is First StepAdvertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
What Does an End-of-Life Doula Do for Patients With Cancer?
5























































